ANI Pharmaceuticals, Inc.

XNASHealth care

Last traded price · USD

$73.17

+2.11%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:06 IST · A quote does not mean the product is available to trade on your account.

Day's open: $73.00
Previous close: $71.65
Volume: 67,413
Day's high: $74.28
Day's low: $71.80

In brief

ANI Pharmaceuticals, Inc. is a health care company listed on Nasdaq, valued at about $1.68B.
Its shares closed at $71.65 on 4 Nov 2026, down 24.2% over the past year.
From India you can buy ANIP in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy ANI Pharmaceuticals, Inc. (ANIP) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ANIP share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ANIP options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +0.2% (SPY −1.6%, XLV +13.5%). 3 months: −10.3% (SPY −0.4%, XLV +15.5%). 1 year: −24.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ANIP, SPY and XLV · as of 4 Nov 2026
3.0% above its 52-week low
Closed at $71.65 on 4 Nov 2026: 24.9% below the 52-week high of $95.45 (7 Nov 2025) and 3.0% above the low of $69.58 (11 Sep 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
10.1 days to cover short interest
3.5M shares were sold short at the 15 Oct 2026 settlement, 15.1% of the 23.0M shares outstanding; covering them would take 10.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $71.65 was 1.5% below its 50-day average ($72.74) and 7.5% below its 200-day average ($77.45). It has closed below the 200-day for 63 sessions, since 7 Aug 2026. The 50-day average crossed below the 200-day on 27 Aug 2026, 48 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+0.2%

6 months−14.8%

1 year−24.2%

5 years+43.3%

Newswire

About

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Website

Notable moves

August 8, 2025
+18.07%
March 15, 2022
−18.65%
November 1, 2021
+49.52%

Newswire

About

Website

Notable moves

August 8, 2025
+18.07%
March 15, 2022
−18.65%
November 1, 2021
+49.52%

ANI Pharmaceuticals, Inc.

XNASHealth care

Last traded price · USD

$73.17

+2.11%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:06 IST · A quote does not mean the product is available to trade on your account.

Day's open: $73.00
Previous close: $71.65
Volume: 67,413
Day's high: $74.28
Day's low: $71.80

In brief

ANI Pharmaceuticals, Inc. is a health care company listed on Nasdaq, valued at about $1.68B.
Its shares closed at $71.65 on 4 Nov 2026, down 24.2% over the past year.
From India you can buy ANIP in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy ANI Pharmaceuticals, Inc. (ANIP) shares from India?

Do I need the price of a whole ANIP share to invest?

How much can I invest in US stocks in a year?

Can I trade ANIP options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +0.2% (SPY −1.6%, XLV +13.5%). 3 months: −10.3% (SPY −0.4%, XLV +15.5%). 1 year: −24.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ANIP, SPY and XLV · as of 4 Nov 2026
3.0% above its 52-week low
Closed at $71.65 on 4 Nov 2026: 24.9% below the 52-week high of $95.45 (7 Nov 2025) and 3.0% above the low of $69.58 (11 Sep 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
10.1 days to cover short interest
3.5M shares were sold short at the 15 Oct 2026 settlement, 15.1% of the 23.0M shares outstanding; covering them would take 10.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $71.65 was 1.5% below its 50-day average ($72.74) and 7.5% below its 200-day average ($77.45). It has closed below the 200-day for 63 sessions, since 7 Aug 2026. The 50-day average crossed below the 200-day on 27 Aug 2026, 48 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+0.2%

6 months−14.8%

1 year−24.2%

5 years+43.3%

Newswire

About

Website

Notable moves

August 8, 2025
+18.07%
March 15, 2022
−18.65%
November 1, 2021
+49.52%

Newswire

About

Website

Notable moves

August 8, 2025
+18.07%
March 15, 2022
−18.65%
November 1, 2021
+49.52%

ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

3.0% above its 52-week low

10.1 days to cover short interest

Below its 50- and 200-day averages

ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

3.0% above its 52-week low

10.1 days to cover short interest

Below its 50- and 200-day averages